ArticleCancer cell international2026
Integrating MRI radiomics and transcriptomics to predict IDH mutation status and prognosis in glioma.
Article in Cancer cell international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectiveTo investigate MRI-based radiomic features in glioma and key genes related to IDH mutations, and to analyze their correlation.
methods61 MRI files from TCIA were divided into training and validation sets (7:3). An external validation set included 66 pathologically confirmed glioma patients. Regions of interest (ROIs) were manually delineated, extracting 1,037 radiomic features. Mann-Whitney U test and least absolute shrinkage and selection operator (LASSO) regression reduced and filtered features. RNA-seq data differential analysis identified key genes linked to glioma progression and IDH mutations. To ensure the comprehensiveness and robustness of our findings, we further validated the protein expression, tumor immune microenvironment, and cellular localization of these key genes utilizing Western blotting, immune infiltration analysis, single-cell RNA sequencing, and spatial transcriptomics. Correlation between radiomic features and key IDH mutation genes was analyzed.
resultsA model with nine IDH mutation-related radiomic features showed strong predictive performance. Univariate and multivariate Cox regression indicated these features predict glioma prognosis. Eight radiomic features differed significantly across MGMT methylation levels. Differential analysis identified eight key genes promoting glioma development and associated with IDH mutations. Crucially, Western blot experiments confirmed the differential expression of these proteins across IDH subtypes. Furthermore, single-cell and spatial transcriptomic analyses revealed that these genes are predominantly expressed in specific cellular subpopulations, such as astrocytes and microglia, and correlate with immune infiltrating cells, contributing to glioma malignancy. Among the nine selected radiomic features (RF1-RF9), RF3 and RF7 were significantly negatively correlated with key IDH mutation genes, while RF4 showed significant positive correlation. RF2 and RF6 exhibited significant negative correlations with MMP9.
conclusionMRI-based radiomic features and models are valuable for predicting IDH mutations in gliomas. Combined with bioinformatics analysis, they aid in identifying glioma pathological types and genetic characteristics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.